Core Viewpoint - Jacobson Pharma and Genetron Holdings announced a new licensing agreement with Europharma, which will provide manufacturing space for Genetron in Hong Kong, effective from December 1, 2025, to January 27, 2028, with a monthly fee of HKD 247,000 [1] Group 1 - The 2025 Europharma licensing agreement is established due to the expiration of a previous licensing agreement in November 2025 [1] - Europharma is a wholly-owned subsidiary of Jacobson Pharma, while Europharma (Hong Kong) is a wholly-owned subsidiary of Genetron Holdings [1] - Since 2007, Europharma has been leasing factory space in the Science Park for pharmaceutical manufacturing [1] Group 2 - The new licensing arrangement will generate rental income from unused factory space for Europharma and provide suitable manufacturing facilities for Europharma (Hong Kong) [1] - Relocating Europharma (Hong Kong)'s existing facilities that comply with pharmaceutical production quality management standards is costly and time-consuming [1] - The 2025 Europharma licensing agreement allows Europharma (Hong Kong) to continue operations without interruption and avoid relocation expenses [1]